MedTrace Logo

Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults

NCT04313127 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2021-08-04

No results posted yet for this study

Summary

The 2019 novel-coronavirus (2019-nCov) is the cause of a cluster of unexplained pneumonia that started in Hubei province in China. It has manifest into a global health crisis with escalating confirmed cases and spread across many countries.

In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of diseases caused by COVID-19 can be tough for current treatment.

This study is a phase I clinical trial. The investigators intent to evaluate the safety, reactogenicity and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) .

Conditions

Interventions

BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intramuscular other name:Ad5-nCoV

Sponsors & Collaborators

  • Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China

    collaborator OTHER

  • Jiangsu Province Centers for Disease Control and Prevention

    collaborator NETWORK

  • Hubei Provincial Center for Disease Control and Prevention

    collaborator OTHER

  • Tongji Hospital

    collaborator OTHER

  • CanSino Biologics Inc.

    lead INDUSTRY

Principal Investigators

  • Zhu Fengcai · Jiangsu Province Centers for Disease Control and Prevention

  • Guan Xuhua · Hubei Provincial Center for Disease Control and Prevention

  • Wang Wei · Tongji Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-16
Primary Completion
2021-01-20
Completion
2021-02-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04313127 on ClinicalTrials.gov